PLM60 for Peripheral T Cell Lymphoma (PTCL)

Status Withdrawn

Clinical Trial Summary

This is a Phase 1-2, randomized, multicenter, open label study of PLM60 administered via intravenous (IV) infusion in 28 day treatment cycles to adult participants with relapsed or refractory Peripheral T Cell Lymphoma (PTCL).

Clinical Trial Description

The study is designed to identify and characterize the safety, tolerability, efficacy, and the PK profile of PLM60 in patients with relapsed or refractory PTCL. Phase 1 will explore multiple dose levels and select a single dose level in Phase 2 to more effectively assess efficacy in the PTCL population. It is anticipated that up to approximately 30 participants will be enrolled during Phase 1. The actual number enrolled, however, will depend on the number of dose-limiting toxicity (DLT)-evaluable participants that complete the first cycle of therapy. Phase 2 will enroll up to 34 participants at the RP2D, some of whom will have been enrolled during Phase 1. Consequently, up to approximately 55 participants will be treated in the study as a whole. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03553914
Study type	Interventional
Source	Conjupro Biotherapeutics
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	January 2021
Completion date	January 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04526834` - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT04390737` - Evaluate the Safety and Clinical Activity of HH2853	Phase 1/Phase 2
Recruiting	`NCT05559008` - A Umbrella Study in R/R PTCL Guided by Molecular Subtypes	Phase 1/Phase 2
Recruiting	`NCT06083701` - Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study	Phase 1/Phase 2
Not yet recruiting	`NCT02856997` - Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma	Phase 2
Recruiting	`NCT04083495` - CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma	Phase 2
Not yet recruiting	`NCT05979792` - Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma	Early Phase 1
Recruiting	`NCT04984837` - Study of Lacutamab in Peripheral T-cell Lymphoma	Phase 2
Recruiting	`NCT06072131` - To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL	Phase 3
Completed	`NCT01716806` - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)	Phase 2
Terminated	`NCT03947255` - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma	Phase 2
Recruiting	`NCT04028440` - γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)	Early Phase 1
Not yet recruiting	`NCT05923502` - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Recruiting	`NCT05377827` - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	Phase 1
Recruiting	`NCT05883449` - Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL	Phase 2
Active, not recruiting	`NCT03586999` - Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas	Phase 1/Phase 2
Recruiting	`NCT04489264` - The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Recruiting	`NCT06151106` - Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma	Phase 2
Recruiting	`NCT02753543` - Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma	Phase 2
Not yet recruiting	`NCT06089941` - Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas